|
|
Article: ILEX Raises $93.5M In Secondary Public Offering Of Common Stock.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
ILEX Oncology Inc. gained gross proceeds of $93.5 million through the sale of 5.5 million common shares priced at $17 apiece.
The San Antonio-based company said it netted $87.5 million in the offering - funds it plans to use for product development, financing clinical trials and preclinical work.
"We want to continue to develop our compounds in different areas and various phases of testing," Mark Mellin, ILEX's chief financial officer, told BioWorld Today. "We also need to take a look at potential in-licensing opportunities and acquisitions of complementary products. It's a combination of those, and we figured it was the right time ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|